Efficacy News and Research

RSS
Boehringer Ingelheim completes patient enrolment of two pivotal Phase III interferon-free hepatitis C clinical trials

Boehringer Ingelheim completes patient enrolment of two pivotal Phase III interferon-free hepatitis C clinical trials

Oraya Therapy Stereotactic Radiotherapy for treatment of wet AMDs now available at Optegra

Oraya Therapy Stereotactic Radiotherapy for treatment of wet AMDs now available at Optegra

Women diagnosed for menopause after breast cancer may vary with type of doctors

Women diagnosed for menopause after breast cancer may vary with type of doctors

FDA: New drug Tivicay approved to treat HIV-1 infection

FDA: New drug Tivicay approved to treat HIV-1 infection

Harvard University receives grant to use organs-on-chips device to test human response to radiation

Harvard University receives grant to use organs-on-chips device to test human response to radiation

Study provides efficient strategy for prevention of rotavirus infection

Study provides efficient strategy for prevention of rotavirus infection

One-third of patients with heart pumps develop infection at abdominal power connection site

One-third of patients with heart pumps develop infection at abdominal power connection site

AmpliPhi releases data on phage therapy for treatment of lung infections in Cystic Fibrosis patients

AmpliPhi releases data on phage therapy for treatment of lung infections in Cystic Fibrosis patients

Teplizumab to block type 1 diabetes proves strikingly effective in phase 2 clinical trial

Teplizumab to block type 1 diabetes proves strikingly effective in phase 2 clinical trial

Autologous tumor cell vaccination: An effective strategy to advance long-term leukemia control

Autologous tumor cell vaccination: An effective strategy to advance long-term leukemia control

UCLA researchers combine cellular and gene therapies to develop treatment for breast cancer

UCLA researchers combine cellular and gene therapies to develop treatment for breast cancer

Researchers improve efficacy of RASV by modifying pathogen’s ability to survive in hostile environment

Researchers improve efficacy of RASV by modifying pathogen’s ability to survive in hostile environment

Ensemble Therapeutics initiates research and development collaboration with Novartis

Ensemble Therapeutics initiates research and development collaboration with Novartis

Regeneron, Bayer report positive results from Phase 3 VIVID-DME and VISTA-DME trials of EYLEA for DME

Regeneron, Bayer report positive results from Phase 3 VIVID-DME and VISTA-DME trials of EYLEA for DME

Signaling protein involved in inflammation also promotes tumor resistance to anti-angiogenic therapy

Signaling protein involved in inflammation also promotes tumor resistance to anti-angiogenic therapy

NanoViricides, LRRI sign NDA for IND-enabling efficacy studies on FluCide drug candidates

NanoViricides, LRRI sign NDA for IND-enabling efficacy studies on FluCide drug candidates

European authorisation of Aegerion Pharmaceuticals' Lojuxta brings hope for HoFH patients

European authorisation of Aegerion Pharmaceuticals' Lojuxta brings hope for HoFH patients

Jersey Shore hospital participates in clinical study of investigational vaccine for prevention of CDI

Jersey Shore hospital participates in clinical study of investigational vaccine for prevention of CDI

Combating antibiotic resistance: an interview with Ron Najafi, CEO NovaBay Pharmaceuticals

Combating antibiotic resistance: an interview with Ron Najafi, CEO NovaBay Pharmaceuticals

Clinicians should be aware of use of herbal supplements while breastfeeding

Clinicians should be aware of use of herbal supplements while breastfeeding

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.